The Pharmaceutical care of patients with type 2 diabetes mellitus
- 588 Downloads
Objective To evaluate the efficiency of pharmaceutical care on the control of clinical parameters, such as fasting glycaemia and glycosylated haemoglobin in patients with Type 2 Diabetes mellitus. Setting This study was conducted at the Training and Community Health Centre of the College of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. Methods A prospective and experimental study was conducted with 71 participants divided in two groups: (i) pharmaceutical care group (n=40), and (ii) the control group (n=31). The distribution of patients within these groups was made casually, and the patients were monitored for 12 months. Main outcome measure: Values for fasting glycaemia and glycosylated haemoglobin were collected. Results Mean values of fasting glycaemia in the pharmaceutical care group were significantly reduced whilst a small reduction was detected in the control group at the same time. A significant reduction in the levels of glycosylated haemoglobin was detected in patients in the pharmaceutical care group, and an average increase was observed in the control group. Furthermore, the follow-up of the intervention group by a pharmacist contributed to the resolution of 62.7% of 142 drug therapy problems identified. Conclusion In Brazil, the information provided by a pharmacist to patients with Type 2 Diabetes mellitus increases compliance to treatment, solving or reducing the Drug Therapy Problem and, consequently, improving glycaemic control.
KeywordsBrazil Brazilian Public Health System Compliance Fasting glycaemia Glycosylated haemoglobin Pharmacist Pharmaceutical Care Type 2 Diabetes mellitus
The authors would like to thank all the patients who participated in this study.
The study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Conflicts of Interest
The authors have no conflicts of interest to disclose.
- 1.International Diabetes Federation. Diabetes Atlas. 4th ed. Brussels: International Diabetes Federation; 2009. 100p. (ISBN - 13: 978-2-930229-71-3). Available: http://www.diabetesatlas.org/content/diabetes.
- 2.World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Geneva: World Health Organization; 2006. 52p. (ISBN - 92-4-159493-4). Available: http://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf.
- 6.Pereira LRL, Freitas O. The evolution of pharmaceutical care and the prospect for the Brazil. Braz J Pharm Sci. 2008;44(4):601–12.Google Scholar
- 7.Castro MS, Chemello C, Pilger D, Junges F, Bohnen L, Zimmerman LM, et al. Pharmaceutical care in the management of patients with hypertension. Braz J Hypertens. 2006;13(3):198–202.Google Scholar
- 8.Lyra-Júnior DP, Kheir N, Abriata JP, Rocha CE, Santos CB, Pelá IR. Impact of pharmaceutical care interventions in the identification and resolution of drug-related problems and on quality of life in a group of elderly outpatients in Ribeirão Preto (SP), Brazil. Ther Clin Risk Manag. 2007;3(6):989–98.Google Scholar
- 23.United Kingston Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317(7160):703–13.Google Scholar
- 28.World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva: WHO publications; 2003. 211p. (ISBN – 92-4-154599-2). Available: http://apps.who.int/medicinedocs/en/d/Js4883e/.